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Original Investigation | Geriatrics
Association of ReceivingMultiple, Concurrent Fracture-Associated Drugs
With Hip Fracture Risk
Rebecca T. Emeny, PhD, MPH; Chiang-Hua Chang, PhD; Jonathan Skinner, PhD; A. James O’Malley, PhD; Jeremy Smith, MPH; Gouri Chakraborti, MA;
Clifford J. Rosen, MD; Nancy E. Morden, MD, MPH
Abstract
IMPORTANCE Many prescription drugs increase fracture risk, which raises concern for patients
receiving 2 or more such drugs concurrently. Logic suggests that risk will increase with each
additional drug, but the risk of taking multiple fracture-associated drugs (FADs) is unknown.
OBJECTIVE To estimate hip fracture risk associated with concurrent exposure to multiple FADs.
DESIGN, SETTING, AND PARTICIPANTS This cohort study used a 20% random sample of Medicare
fee-for-service administrative data for age-eligible Medicare beneficiaries from 2004 to 2014.
Sex-stratified Cox regressionmodels estimated hip fracture risk associated with current receipt of 1,
2, or 3 or more of 21 FADs and, separately, risk associated with each FAD and 2-way FAD combination
vs no FADs. Models included sociodemographic characteristics, comorbidities, and use of non-FAD
medications. Analyses began in November 2018 and were completed April 2019.
EXPOSURE Receipt of prescription FADs.
MAINOUTCOMESANDMEASURES Hip fracture hospitalization.
RESULTS A total of 11.3 million person-years were observed, reflecting 2 646 255 individuals (mean
[SD] age, 77.2 [7.3] years, 1 615 613 [61.1%] women, 2 136 585 [80.7%] white, and 219 579 [8.3%]
black). Overall, 2 827 284 person-years (25.1%) involved receipt of 1 FAD; 1 322 296 (11.7%), 2 FADs;
and 954 506 (8.5%), 3 or more FADs. In fully adjusted, sex-stratified models, an increase in hip
fracture risk among womenwas associated with the receipt of 1, 2, or 3 or more FADs (1 FAD: hazard
ratio [HR], 2.04; 95%CI, 1.99-2.11; P < .001; 2 FADs: HR, 2.86; 95%CI, 2.77-2.95; P < .001;3 FADs:
HR, 4.50; 95% CI, 4.36-4.65; P < .001). Relative risks for men were slightly higher (1 FAD: HR, 2.23;
95%CI, 2.11-2.36; P < .001; 2 FADs: HR, 3.40; 95%CI, 3.20-3.61; P < .001;3 FADs: HR, 5.18; 95%CI,
4.87-5.52; P < .001). Amongwomen, 2 individual FADs were associated with HRs greater than 3.00;
80 pairs of FADs exceeded this threshold. Common, risky pairs among women included sedative
hypnotics plus opioids (HR, 4.90; 95% CI, 3.98-6.02; P < .001), serotonin reuptake inhibitors plus
benzodiazepines (HR, 4.50; 95% CI, 3.76-5.38; P < .001), and proton pump inhibitors plus opioids
(HR, 4.00; 95% CI, 3.56-4.49; P < .001). Receipt of 1, 2, or 3 or more non-FADs was associated with a
small, significant reduction in fracture risk compared with receipt of no non-FADs among women (1
non-FAD: HR, 0.93; 95% CI, 0.90-0.96; P < .001; 2 non-FADs: HR, 0.84; 95% CI, 0.81-0.87; P < .001;
3 non-FADs: HR, 0.74; 95% CI, 0.72-0.77; P < .001).
CONCLUSIONS ANDRELEVANCE Among older adults, FADs are commonly used and commonly
combined. In this cohort study, the addition of a second and third FAD was associated with a steep
increase in fracture risk. Many risky pairs of FADs included potentially avoidable drugs (eg, sedatives
and opioids). If confirmed, these findings suggest that fracture risk could be reduced through tighter
(continued)
Key Points
Question Is the concurrent receipt of 2
fracture-associated drugs associated
with increased risk of hip fracture?
Findings In this cohort study, 11 million
person-years of Medicare data revealed
that the receipt of multiple fracture-
associated drugs was common among
older US residents. Concurrent receipt
of 2 or more such drugs was associated
with amore than 2-fold increase in hip
fracture risk, with some specific
combinations appearing especially
hazardous, including commonly
prescribed drugs, such as opioids,
antidepressants, and sedatives.
Meaning If confirmed, results of this
cohort study suggest caution when
combining fracture-associated
medications, especially when use is
discretionary, alternatives exist, or
baseline fracture risk is high.
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adherence to long-established prescribing guidelines and recommendations.
JAMA Network Open. 2019;2(11):e1915348.
Corrected on December 11, 2019. doi:10.1001/jamanetworkopen.2019.15348
Introduction
At least 21 prescription drug groups have been associated with increased fracture risk.1-12 The list
includes some of themost commonly used products in the United States, such as opioids, proton
pump inhibitors (PPIs), serotonin reuptake inhibitors (SSRIs), and sedatives.13 The wide use of many
fracture-associated drugs (FADs) suggests that concurrent receipt of 2 or more may be prevalent.
This in turn raises concern for fracture risk associatedwith such exposure. Logic suggests that risk will
increase with the addition of each additional FAD. However, the fracture risk of such combined drug
use has not been quantified. Understanding the prevalence of concurrent FAD exposure and its risk is
especially important to older people, who have the highest baseline rate of fragility fracture andwho
are most likely to receive multiple FADs as diagnoses and treatments accumulate with age.
Research suggests individual FADs increase fracture risk by weakening bones, increasing falls,
or both. Pathways of bone weakeningmay involve direct skeletal cell effects, disruption of vitamin D
or calciummanagement, modulation of parathyroid hormone effects, and hypogonadism.14-21 The
mechanisms by which medications increase falls include sedation, loss of balance, dizziness, visual
disturbance, muscle weakening, and hypotension.6,9,22-24 A total of 8 drug groups have been
associated with both bone weakening and falls (eTable 1 in the Supplement). The diversity of
mechanismsmakes the net effect of exposure to multiple FADs difficult to predict. Risk associated
with exposure to 2 FADs acting through the same mechanism could prove additive if together the
FADs intensely activate the pathway of harm. Conversely, 2 such drugs could prove redundant,
resulting in no additional risk, if 1 drug alone saturates the pathway. Illuminating and quantifying this
potential iatrogenic source of fracture risk could inform changes in prescribing practices aimed at
reducing risk and the consequences associated with fractures.25-31
Ideally, the study of risks associated with FAD combinations would occur through randomized
clinical trials (RCTs). However, RCTs addressing this question are not readily feasible because of the
large number of potential drug combinations and the need for enormous sample sizes to detect rare
outcomes. Ethical concernswould be raised aswell by trials randomizing people not to receive drugs
known to be effective for specific conditions. Additionally, RCTs often exclude multimorbid, older
individuals and thus may not reveal the risk of such drug regimens in the populations most likely to
receive them.32-34 Well-conducted, population-representative, observational studies thus represent
a crucial opportunity to identify and estimate signals of harm fromdrug combinations. Such signals,
if strong and reproducible, could inform basic science research exploring biological pathways of risk
and perhaps effective harm reduction strategies; they could also help justify and prioritize carefully
conducted, narrowly focused RCTs.35-38
We usedMedicare administrative data to examine hip fracture risk associated with prescription
receipt. We first modeled hip fracture risk associated with overall drug count, then with FAD count
and count of other drugs (non-FADS) to examine these broad categories separately. We then
modeled risk of hip fracture associated with 21 individual FADs and their 210 possible 2-way
combinations vs no FADs.
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Methods
Data and Cohort
We usedMedicare Parts A (inpatient) and B (outpatient) administrative data from 2004 to 2014 and
Medicare Part D (prescription) records from 2006 to 2014 for a 20% random sample of fee-for-
service enrollees. For cohort inclusion, we identified age-eligible beneficiaries with a minimum of 24
months of Parts A and B coverage from 2004 to 2014 plus at least 12 additional months of A, B, and
D coverage from 2006 to 2014 (eFigure 1 in the Supplement). Thus, age-eligible individuals were 67
years or older at the time of first observation. The 24 months before the observation period were
required to ascertain past morbidities and past fractures. We excluded patients with a fragility
fracture (ie, hip, wrist, humerus, and vertebra) apparent in the 24-month preobservation period. This
exclusion conservatively created a relatively homogeneous, lower-risk cohort for exploration of FAD
risks in the general, geriatric population. Additionally, patients with any of the following diagnoses or
services during the study period were excluded: cancer (except nonmelanoma skin cancer),
advanced renal disease, vertebral fracture, or hospice. Fracture and disease definitions appear in
eTable 2 in the Supplement, and exclusion justification appears in the eAppendix in the Supplement.
We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
reporting guideline.39 The Dartmouth Protection of Human Subjects Committee approved this study
and granted a waiver of written informed consent because risk was deemedminimal and research
involvedmaterials collected for nonresearch purposes.
Prescription Receipt
From published studies andmeta-analyses we identified 21 distinct FAD groups including,
antipsychotics, opioids, thiazide diuretics, loop diuretics, glucocorticoids, PPIs, sedative hypnotics,
and SSRIs.1-12,40 The full drug list is provided in eTable 3 in the Supplement.We identified prescription
receipt from the Medicare Prescription Drug Event file. For analysis, the data were structured such
that, for each drug group, each person-day was assigned as currently exposed or unexposed. Current
exposure was assumed to begin on the date of prescription dispensing. We used days supply to set
exposure duration. This same approach was applied to other systemic drugs (non-FADs) which were
aggregated into 4 current exposure variables (ie, 0, 1, 2, and3 non-FADs) for models. The
eAppendix in the Supplement explains FAD and non-FAD ascertainment via National Drug Codes
identified by Lexicomp Basic database (Wolters Kluwer) and First Databank (First Databank),
respectively. Three types of fracture-protective drugs were also recorded as time varying by
person-day and included in eachmodel as currently exposed or not exposed, as follows: (1) estrogen
(eg, systemic estrogen, selective estrogen receptor modulators), (2) osteoporosis medications (eg,
bisphosphonates, calcitonin, parathyroid hormone, denosumab), and (3) β-blockers.41-48 Each
intravenous zoledronic acid dose (retrieved from theMedicare Part B Carrier File) was assumed to
confer 12 months of bisphosphonate exposure (eAppendix and eTable 3 in the Supplement).
Outcome
We identified hip fracture diagnosis codes from inpatient claims.12,49 Outcome date was hip fracture
admission date.We focused on hip fractures because inpatient-treated hip fractures are temporally
discrete events with a precise event date.50 This permits accurate sequencing of exposure and
outcome, assuring we don’t attribute fracture risk to drugs received after the fracture. This is
especially important in the study of opioids, which are often used to treat fracture pain (eTable 2 in
the Supplement).
Covariates
We ascertained the following covariates for model inclusion. From theMedicare enrollment files, we
obtained age (classified as aged 67-69 years; thereafter in 5-year groups), sex, race/ethnicity, original
Medicare entitlement reason, Medicaid eligibility, and Part D Low-Income Subsidy status. We
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dichotomized the latter 2 variables for each calendar year, assigning the status if present 1 or more
months. Long-term care (LTC) status was assigned if 50% or more of prescriptions in a year were
dispensed by an LTC pharmacy (retrieved from Part D Pharmacy Characteristics file). From inpatient
and outpatient claims, we identified 22 morbidities and assigned patients to each (dichotomous
indicator variable) on the first observed diagnosis code at any point in the study. In selecting
morbidities for models, we began with the Charlson Comorbidity Index list.51 From this list we
dropped cohort exclusion conditions (ie, renal failure and cancer) as well as HIV/AIDS because of
extremely low prevalence; we then added conditions associated with falls or fractures, eg, seizure
disorder, osteoporosis, tobacco use, depression, rheumatologic disease, and alcohol use (eTable 2 in
the Supplement). Morbidities and LTC were considered absorptive states, ie, once present,
always present.
Statistical Analysis
Our principal aimwas to estimate hip fracture risk associated with current exposure to FAD
combinations. Preliminary models estimated risk associated with overall number of drugs.52,53 Main
models estimated risk associatedwith FAD count and non-FAD count and, separately, risk associated
with individual FADs and 210 possible 2-way FAD combinations. All models were stratified by sex,
an anticipated effect modifier.
For time-varying exposure analysis, each person-day was assigned 1 of 233mutually exclusive
FAD exposure categories: 0 FADs, 21 single FADs, 210 possible 2-way FAD combinations, or an
aggregate of 3 or more FADs. For statistical reliability, 2-way exposures with less than 100 person-
years (PYs) observation in each sex-specific cohort were grouped into a category called FAD pairs
with fewer than 100 PYs. We calculated crude fractures per 1000 PYs and percentage of total PYs of
observation for each exposure category by sex. Age group–specific crude fracture rates were also
calculated.
We applied Cox regressionmodels to counting-process data54,55 and estimated drug-associated
fracture risk in the 3 following ways: (1) risk associated with current total drug count (FADs and
non-FADs), (2) risk associated with current FAD count category and non-FAD count category (1, 2,
and3) vs no drugs, and (3) risk associated with 231 single and 2-way exposure indicators plus an
indicator of 3 or more concurrent FADs vs no FADs. These models of specific single and 2-way FAD
pairs included indicators of non-FAD exposure (ie, 0, 1, 2, or3). All models included the covariates
described earlier, ie, age, sociodemographic factors, comorbidities, and 3 indicators for fracture-
protective drugs.
In these models, individuals may have contributed to a variety of exposure groups (including no
exposure) as the number and type of drugs they received changed over time. The regression
coefficient for each exposure indicator was the fracture risk associated with being in that receipt
status vs receiving no FADs. Patients were censored at death; disenrollment from fee-for-service
Parts A, B, or D; or first hip fracture.
To explore residual confounding, we repeated sex-specific, categorical exposure (ie, 0, 1, 2, or
3) models, stratified by age group. We reasoned that drug count may be a proxy for unrecorded
disease and disease severity (potential confounders); both commonly increase with age. We
expected fracture risk associated with FADs and non-FADs to increase across progressively older age
groups if residual confounding were substantial.
Sensitivity analyses includedmodels with no drug exposure indicators; these were intended to
explore estimates associatedwith known risk factors, such as chronic conditions, when detailed drug
exposure was not considered (eTable 6 in the Supplement). Separate sensitivity analyses repeated
main models but included consideration of competing risk of death using both subdistribution and
cause-specific hazards (eAppendix in the Supplement).
Analyses were initiated in November 2018 and completed April 2019 and conducted with SAS
version 4 (SAS Institute). Statistical tests were 2-sided. After false discovery rate control using the
Benjamini-Hochberg procedures,56 risk estimates with P < .05 were considered significant.
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Results
Cohort Characteristics
Our cohort included 2 646 255 beneficiaries with 11 286 768 PYs of observation. Overall, 1 615 613
beneficiaries (61.1%) were women, 2 136 585 (80.7%) were white individuals, and 219 579 (8.3%)
were black individuals. Mean (SD) age was 77.2 (7.3) years at study conclusion. Mean (SD)
observation time was 4.3 (2.8) years. Over the 9-year study, 726 704 cohort members (27.5%)
received Part D LIS, 611 006 (23.1%) were Medicaid eligible, and 211 128 (8.0%) received an LTC
assignment (Table 1).
Exposure andOutcomes
Overall, 2 827 284 PYs (25.1%) involved receipt of 1 FAD; 1 322 296 (11.7%), 2 FADs; and 954 505
(8.5%), 3 or more FADs. Among women, 1 827 305 PYs (25.6%) were exposed to 1 FAD, 912 855
(12.8%) to 2 FADs, and 705 500 (9.9%) to 3 ormore FADs; exposure inmenwas slightly lower (1 FAD,
999979 PYs [24.0%]; 2 FADs, 409441 PYs [9.8%];3 FADs, 249006 PYs [6.0%]) (Table 2). Over
the 9-year period, 1 000 118 women (61.9%) and 533 604men (51.8%) received 2 FADs on 1 or more
days; 640 178 women (39.6%) and 294 181 men (28.5%) received 3 or more concurrent FADs on 1
or more days (eTable 4 in the Supplement). Women received more fracture-protective drugs than
men. The most common FAD exposures (alone or in combination with other FADs) were opioids
(463 419 PYs of exposure), thiazides (1 447094 PYs of exposure), prescription PPIs (941 159 PYs of
exposure), and SSRIs (763 953 PYs of exposure) (eTable 4 in the Supplement). After uncommon
2-way exposures were grouped as FAD pairs with fewer than 100 PYs, themodel for women included
204 exposures (27 pairs grouped), and themodel formen included 186 exposures (45 pairs grouped)
(eTable 5 in the Supplement).
We observed 59 704 hip fractures, 47 386 (79.4%) among women and 12 317 (20.6%) among
men. Crude hip fracture rate was 6.65 per 1000 PYs among women and 2.96 per 1000 PYs among
men (Table 2), replicating published rates.50
Fracture Risk AssociatedWith Drug Count
For women, crude fracture rate associated with 0 FADs was 3.34 per 1000 PYs; 1 FAD, 6.47 per 1000
PYs; 2 concurrent FADs, 10.38 per 1000 PYs; and 3 or more FADs, 19.55 per 1000 PYs. Amongmen,
corresponding rates were 1.45 per 1000 PYs, 3.15 per 1000 PYs, 5.95 per 1000 PYs, and 12.51 per
1000 PYs, respectively. Crude fracture rates associatedwith non-FADs increased in parallel with drug
count but less steeply (eg, for women receiving 0 vs3 non-FADs, 4.44/1000 PYs vs 8.36/1000
PYs; for men receiving 0 vs3 non-FADs, 2.00/1000 PYs vs 3.71/1000 PYs) (Table 2). Age-specific,
crude fracture rates for FADs and non-FADs are presented in the eAppendix and eFigure 2 in the
Supplement.
Fully adjustedmodels exploring total overall drug count and hip fracture risk revealed a hazard
ratio (HR) of 1.10 (95% CI, 1.09-1.10; P < .001) among women and an HR of 1.10 (95% CI, 1.09-1.11;
P < .001) amongmen for each additional drug compared with none (eTable 6 in the Supplement).
Fully adjustedmodels including FAD and non-FAD counts exhibited diverging risks for these broad
drug categories. For women, compared with receiving 0 FADs, receiving 1 FAD was associated with
an HR of 2.04 (95% CI, 1.99-2.11; P < .001); receiving 2 FADs was associated with an HR of 2.86 (95%
CI, 2.77-2.95; P < .001); and receiving 3 FADs or more was associated with an HR of 4.50 (95% CI,
4.36-4.65; P < .001). Comparable non-FAD exposure was associated with an HR of 0.93 (95% CI,
0.90-0.96; P < .001), an HR of 0.84 (95% CI, 0.81-0.87; P < .001), and an HR of 0.74 (95% CI, 0.72-
0.77; P < .001), respectively (Figure 1A; eTable 6 in the Supplement). Among men, compared with
receiving 0 FADs, receiving 1 FAD was associated with an HR of 2.23 (95% CI, 2.11- 2.36; P < .001);
receiving 2 FADs was associated with an HR of 3.40 (95% CI, 3.20-3.61; P < .001); and receiving 3 or
more FADs was associated with an HR of 5.18 (95% CI, 4.87-5.52; P < .001). Comparable non-FAD
exposure was associated with an HR of 0.90 (95% CI 0.84-0.96; P < .001), an HR of 0.84 (95% CI,
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Table 1. Characteristics of Cohort, Composed of a 20%Random Sample of Fee-for-ServiceMedicare
BeneficiariesMeeting Inclusion Criteria, 2006-2014
Characteristic
No. (%)
Overall Women Men
Total
Beneficiaries 2 646 255 (100) 1 615 613 (61.05) 1 030 642 (38.95)
Observation years 11 286 768 (100) 7 126 266 (63.14) 4 160 502 (36.86)
Individual observation time, y
Mean (SD) 4.26 (2.78) 4.41 (2.83) 4.04 (2.70)
Median (IQR) 3.28 (2.00-7.00) 4.00 (2.00-7.22) 3.00 (2.00-6.01)
Age, y
Mean (SD) 77.20 (7.30) 77.85 (7.63) 76.18 (6.61)
Group
67-69 582 479 (22.01) 331 951 (20.55) 250 528 (24.31)
70-74 781 389 (29.53) 445 446 (27.57) 335 943 (32.60)
75-79 540 033 (20.41) 322 991 (19.99) 217 042 (21.06)
80-84 383 473 (14.49) 246 872 (15.28) 136 601 (13.25)
≥85 396 811 (15.00) 287 663 (17.81) 109 148 (10.59)
Race/ethnicity
White 2 136 585 (80.74) 1 298 172 (80.35) 838 413 (81.35)
Black or African American 219 579 (8.30) 147 924 (9.16) 71 655 (6.95)
Hispanic 166 843 (6.30) 99 552 (6.16) 67 291 (6.53)
Asian 86 389 (3.26) 50 085 (3.10) 36 304 (3.52)
Othera 36 859 (1.39) 19 880 (1.23) 16 979 (1.65)
Original reason for Medicare entitlement
Disability 248 882 (9.41) 135 989 (8.42) 112 893 (10.95)
Age 2 397 694 (90.61) 1 479 811 (91.59) 917 883 (89.06)
Medicaid eligibleb 611 006 (23.09) 412 682 (25.54) 198 324 (19.24)
Part D Low-Income Subsidyb 726 704 (27.46) 488 780 (30.25) 237 924 (23.09)
Long-term carec 211 128 (7.98) 150 721 (9.33) 60 407 (5.86)
Hierarchical Conditions Category score, mean (SD) 0.98 (0.94) 0.97 (0.91) 1.01 (0.99)
Chronic conditionsd
Osteoporosis or osteopenia 126 281 (4.77) 116 862 (7.23) 9419 (0.91)
Tobacco use or COPD 357 050 (13.49) 185 073 (11.46) 171 977 (16.69)
Dementia 185 842 (7.02) 127 446 (7.89) 58 396 (5.67)
Obesity 180 431 (6.82) 116 572 (7.22) 63 859 (6.20)
Depression 180 648 (6.83) 133 806 (8.28) 46 842 (4.54)
Serious mental illness 49 592 (1.87) 32 710 (2.02) 16 882 (1.64)
Alcohol use disorder 7841 (0.30) 1999 (0.12) 5842 (0.57)
Diabetes 1 103 209 (41.69) 650 019 (40.23) 453 190 (43.97)
Liver disease 58 335 (2.20) 32 361 (2.00) 25 974 (2.52)
Pancreatic disease 99 952 (3.78) 66 090 (4.09) 33 862 (3.29)
Irritable bowel syndrome 59 679 (2.26) 39 403 (2.44) 20 276 (1.97)
Rheumatologic disease 373 797 (14.13) 270 234 (16.73) 103 563 (10.05)
Spinal cord disease or injury 71 042 (2.68) 42 610 (2.64) 28 432 (2.76)
Serious neurologic disease 435 370 (16.45) 264 824 (16.39) 170 546 (16.55)
Parkinson or Huntington disease 75 637 (2.86) 40 571 (2.51) 35 066 (3.40)
Seizure disorder 137 839 (5.21) 84 025 (5.20) 53 814 (5.22)
Congestive heart failure 735 156 (27.78) 441 880 (27.35) 293 276 (28.46)
Coronary artery disease 596 707 (22.55) 326 111 (20.18) 270 596 (26.26)
Cerebrovascular disease 394 218 (14.90) 240 522 (14.89) 153 696 (14.91)
Peripheral vascular disease 1 007 024 (38.05) 608 263 (37.65) 398 761 (38.69)
Traumatic brain injury 70 450 (2.66) 43 785 (2.71) 26 665 (2.59)
Amputee 17 034 (0.64) 7769 (0.48) 9265 (0.90)
(continued)
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0.79-0.89; P < .001), and an HR of 0.71 (95% CI, 0.67-0.75; P < .001) respectively (Figure 1A;
eTable 6 in the Supplement). Age-stratified analyses revealed no consistent association between
increasing age group and fracture risk associated with FAD count (Figure 1B and Figure 1C; eTable 6
in the Supplement).
Fracture Risk AssociatedWith Specific Drug Pairs
In presenting results of models exploring over 200 distinct exposures, we provided all estimates in
eTable 7 and eTable 8 in the Supplement but focused our report on exposures contributing relatively
Table 1. Characteristics of Cohort, Composed of a 20%Random Sample of Fee-for-ServiceMedicare
BeneficiariesMeeting Inclusion Criteria, 2006-2014 (continued)
Characteristic
No. (%)
Overall Women Men
Mortality 256 687 (9.70) 157 845 (9.77) 98 942 (9.60)
Hip Fracture 59 805 (2.26) 47 337 (2.93) 12 368 (1.20)
Abbreviations: COPD, chronic obstructive pulmonary disease; IQR, interquartile range.
a Includes Native Hawaiian or other Pacific Islander, American Indian or Alaskan Native, and no race/ethnicity given (ie,
replied do not know or refused to all categories).
b Assigned for the full year to beneficiaries qualifying 1 or moremonths in that year; a proxymeasure of poverty.
c Assigned to patients with 50%ormore of prescription fills from a long-term care pharmacy type in a single calendar year.
d Prevalence of conditions are cumulative over the 9-year study period. Health condition assignments are based on 1 or
more service-associated diagnosis. Some diagnoses of alcohol use disorder are missing because of data redaction
associated with addiction care for 2013 to 2014.
Table 2. Fracture Count, Distribution of FAD andNon-FAD Exposure Intensity, and Crude Hip Fracture
Incidence Rate
Outcome
Overall
(N = 2 646 255)
Women
(n = 1 615 613)
Men
(n = 1 030 642)
Total hip fractures, No. 59 703 47 386 12 317
Overall hip fracture rate, fractures per 1000
person-years
5.29 6.65 2.96
Total person-years exposed, No. (%)a
FAD
0 6 182 683 (54.78) 3 680 607 (51.65) 2 502 076 (60.14)
1 2 827 284 (25.05) 1 827 305 (25.64) 999 979 (24.04)
2 1 322 296 (11.72) 912 855 (12.81) 409 441 (9.84)
≥3 954 506 (8.46) 705 500 (9.90) 249 006 (5.98)
Non-FAD
0 3 083 494 (27.32) 1 896 251 (26.61) 1 187 243 (28.54)
1 1 840 513 (16.31) 1 227 066 (17.22) 613 447 (14.74)
2 1 997 982 (17.70) 1 305 244 (18.32) 692 737 (16.65)
≥3 4 364 780 (38.67) 2 697 706 (37.85) 1 667 075 (40.07)
Crude hip fracture rate, fractures per 1000
person-years
FAD
0 2.57 3.34 1.45
1 5.30 6.47 3.15
2 9.00 10.38 5.95
≥3 17.72 19.55 12.51
Non-FAD
0 3.50 4.44 2.00
1 5.01 6.16 2.73
2 5.48 6.80 3.01
≥3 6.58 8.36 3.71
Abbreviations: FAD, fracture-associated drug;
non-FAD, all other prescription drugs that were
not FADs.
a Exposure categories are derived from person-day
level data. For FADs, receipt of 21 single drugs (1 FAD)
and 210 concurrent drug pairs (2 FADs) are classified
for each person and for each day of observation.
Person-days with 3 or more concurrent FADs were
classified as “3 FAD.” The same approach was taken
to identify non-FAD exposures (eAppendix in the
Supplement).
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substantial population-level risk. We defined substantial population effect combinations as those
meeting the 4 following criteria: (1) common (ie, top quintile of exposure PYs), (2) associated with a
2-fold or higher increase in sex-specific, crude, absolute risk, (3) associated with an HR of 3.00 or
more, and (4) associated with 50 or more fractures in our cohort.
Among women, 1 FAD group (ie, muscle relaxers) was associated with no increased fracture risk
when received alone. Significant risks associated with individual FADs ranged from an HR of 1.54
(95% CI, 1.05-2.24; P = .03) for first-generation antipsychotics to an HR of 3.26 (95% CI, 3.04-3.49;
P < .001) for opioids and anHR of 3.29 (95%CI, 2.89-3.76; P < .001) for anti-Parkinson drugs. Among
women, only opioids and anti-Parkinsonmedicationswere associatedwith a relative risk above 3.00,
while 80 combinations exceeded that threshold; 7 of these 80met our population-level impact
criteria. These included opioids plus sedative hypnotics (HR, 4.90; 95% CI, 3.98-6.02; P < .001),
opioids plus loop diuretics (HR, 4.48; 95% CI, 3.96-5.07; P < .001), opioids plus PPIs (HR 4.00; 95%
CI, 3.56-4.49; P < .001), SSRIs plus opioids (HR, 3.91; 95% CI, 3.46-4.43; P < .001), SSRIs plus
benzodiazepines (HR, 4.50; 95% CI, 3.76-5.38; P < .001), SSRIs plus loop diuretics (HR 3.05; 95% CI,
2.75-3.37; P < .001), and nitrates plus loop diuretics (HR, 3.25; 95% CI, 2.84-3.72; P < .001)
(Figure 2A; eTable 7 in the Supplement).
Amongmen, significant risks of single FADs ranged from an HR of 1.51 (95% CI, 1.17-1.95;
P = .002) for sedative hypnotics to an HR of 3.83 (95% CI, 3.36-4.36; P < .001) for opioids and an HR
of 4.23 (95% CI 3.57-5.01; P < .001) for anti-Parkinson drugs. A total of 9 pairs met our population-
level impact criteria; 5 paralleled women’s high-risk pairs (opioids plus loop diuretics, opioids plus
PPIs, SSRIs plus opioids, SSRIs plus loop diuretics, and nitrates plus loop diuretics). Amongmen, the
riskiest drug pairs were opioids plus loop diuretics (HR, 6.93; 95% CI, 5.52-8.70; P < .001) and
opioids plus SSRIs (HR, 6.26; 95% CI, 4.83-8.12; P < .001) (Figure 2B; eTable 8 in the Supplement).
For a small number of FAD pairs, receipt of 2 drugs appeared less risky than receipt of a single
drug. For example, among women, loop diuretics alone were associated an HR of 2.45 (95% CI, 2.32-
2.59; P < .001), but loop diuretics plus centrally acting antihypertensiveswere associatedwith anHR
of 1.82 (95% CI, 1.33-2.49; P < .001) (eTable 7 in the Supplement).
Discussion
Among older Medicare beneficiaries, receipt of FAD combinations is common. Our findings indicated
that fracture risk associatedwith some combinations exceeded individual drug risks. In our study, 20
of 21 examined drug groupswere associatedwith, on average, an approximate 2-fold higher relative
Figure 1. Hip Fracture Hazard Ratios
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Cox regression analysis results are presented as hazard ratios, with 95%CIs presented as
whiskers. Fully adjustedmodels controlled for age, sociodemographic characteristics,
receipt of fracture-protective drugs, and comorbidities. The unit of analysis was person-
day. The models revealed risk associated with current receipt of 1 of 21 individual
fracture-associated drug (FAD) groups, current receipt of 1 of 210 possible FAD pairs, or
any concurrent receipt of 3 or more FADs (eTable 6 in the Supplement). Non-FAD
indicates other systemic drugs.
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Figure 2. Hip Fracture Risk AssociatedWith Select Fracture-Associated Drugs (FADs) and 2-Way Combinations of FADs
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Fully adjusted Cox regression analysis results are presented as hazard ratios and 95%CIs.
Models were stratified by sex and adjusted for age, sociodemographic characteristics,
receipt of fracture-protective drugs, comorbidities, and non-FAD drug receipt. Results
displayed were selected for apparent population-level impact; specifically, combinations
met all 4 of the following criteria: (1) common (ie, top quintile of person-year exposure);
(2) associated with a 2-fold or greater increase in sex-specific, crude, absolute risk; (3)
associated with a relative risk of 3.00 or more; and (4) associated with 50 or more
fractures in our cohort. Only results that achieved a false-discovery rate P < .05 were
considered significant. The unit of analysis was person-day. Full models provided in
eTable 7 and eTable 8 in the Supplement. PPI indicates proton pump inhibitor; SSRI/
SNRI, selective serotonin reuptake inhibitor and selective noradrenergic reuptake
inhibitor; SGAP, second-generation antipsychotic.
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risk of hip fracture. Risk increased steeply with the addition of a second FAD (approximately 3-fold
higher relative risk) and further with a third (more than 4-fold higher relative risk). Many of themost
common, risky pairs included drugs that are relatively contraindicated in our older cohort (eg,
sedative hypnotics and benzodiazepines)57 or potentially discretionary in some patients (eg, PPIs
and opioids). If confirmed, our findings suggest that more cautious prescribing could reduce fracture
risk with few or no negative consequences. The clinical implications of risk associated with essential
medications (eg, loop diuretics and nitrates) will depend on anticipated net effect (ie, risk plus
benefit). That opioids were included in many high-risk pairs reflected their frequent use and
associated risk; this findingmight reinforce ongoing scrutiny of opioid-prescribing practices.
Our study built on past efforts to estimate risk associated with complex prescription drug
combinations. Our results did not support a common approach of defining problematic drug
regimens (ie, polypharmacy) based on numeric cutoffs.We found substantial risk associatedwith just
2 or 3 FADs, counts well below a popular polypharmacy definition of five or more.58 Equally
important, we found receipt of 3 ormore non-FADs associatedwith a slightly reduced risk of fracture,
indicating that moremay be better in some cases. These results suggested that a nuanced approach
is needed to assess medication count, combinations, and risk. One such nuanced approach is
exemplified by the anticholinergic burden framework that explicitly addresses the additive nature of
adverse effects resulting from concurrent use ofmultiple anticholinergic drugs.59 Our study similarly
considered combinations of drugs with an overlapping adverse effect risk. A total FAD burden
conceptual framework may be valuable. Verified estimates could inform risk reduction efforts and
risk calculators, such as the Fracture Risk Assessment Tool, which currently considers just 1
prescription group (ie, glucocorticoids).60,61
While many studies demonstrate that both type and number of medications are associatedwith
fall and fracture risk, our work expanded understanding by examining drugs associatedwith fracture
through a fall-inducing mechanism and those associated with fracture because of bone
weakening.62-67 We examined these drugs in detail through identification of time-varying exposure
to specific FADs and specific FAD pairs, controlling for non-FAD drug receipt. We cannot tell which
mechanisms contributed to observed excess risks. We can imagine that combining an opioid with a
sedative hypnotic could result in extreme sedation or loss of balance, but the mechanismmay be
more complex. Like many FADs, opioids have been shown to increase falls and weaken bones.68-70
Disease-disease interactions or disease-drug interactions could contribute to observed effects. How
a drug might mitigate the fracture-promoting effect of another is equally elusive. This has been
suggested by others, but such research is nascent.42,71 Understanding themechanisms of harm and
protection could inform effective risk reduction strategies.
We found FAD-associated relative risk of hip fracture higher amongmen than women. This
excess relative risk occurred in the context of lower absolute risk for men, but the findingmay have
important implications becausemen experience higher mortality after hip fracture than women.72-74
Sex differences in FAD risks may be an important priority for future research.
Limitations
Our work has limitations. First, our observational study could suffer from residual confounding if FAD
use is related to unobserved behavioral risk factors, unrecorded diseases, or disease severity beyond
that controlled for (eg, biological risk factors such as balance and bodymass). However, age-group
stratified models revealed no increasing risk associated with increasing age group as might be
expected given that unobservable confounding is likely more of a problem in older populations; this
reduces but does not eliminate residual confounding concerns. Some diseases are inseparable from
treatments; for example, Parkinson disease and treatments are both associated with fracture. Our
models revealed how the addition of other, potentially discretionary FADs to Parkinson drugs may
further increase risks. The estimates of known risk factors, such as age and comorbidities, were
abrogated by increasing granularity of drug exposure, as demonstrated in eTable 6 in the
Supplement.
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Second, our exposure measure was based on prescription fills. The extent to which patients fill
but do not take medications, take medications over periods distinct from days supply, or obtain
medications through unobserved channels will bias our results. Third, we observed current exposure
and classified it dichotomously within drug groups; we did not consider dose, specific drugs within a
drug group, cumulative exposure, or recency of FAD initiation. We expect neglecting these factors
that influence fracture risk would shift our results toward the null. Future work considering these
details will provide deeper understanding of risks because, for example, initiation of drug use has
been associated with greatest risk.10,75 Fourth, we studied hip fractures; how FAD combinations
affect other fragility fractures should be explored. Fifth, Part D coverage for benzodiazepines was
limited until 2013; benzodiazepine exposure in early years is likely underestimated.76 Sixth, we
observed effect estimates for single exposures that aligned with other large-scale studies; thus, our
observational design and analytic approach replicated published results.3,23,75,77-84 Nonetheless,
some drugs we classified as FADs have heterogeneous associations in the literature; some studies
find them fracture-associated, others fracture-protective or neutral. We included them to be
thorough and to add to the knowledge base. Furthermore, our results may not be generalizable to
other populations.
Conclusions
Our cohort study is hypothesis generating and suggests future research directions. Follow-up studies
should explore factors influencing use (and combination use) of potentially avoidable drugs
associated with substantial fracture risk. To support clinical decision-making, studies should explore
FAD risk in the context of anticipated benefits of essential drugs. Our findings suggested a need to
update and refine our conceptual approach to identifying problematic drug regimens, moving past
count and appropriateness in favor of nuanced considerations of overlapping risks and benefits.
Large data sets and emerging advanced analytic approaches, such asmachine learning, may facilitate
these efforts as that science and its application to health care data mature.85 The exploration of
mechanisms through which FAD pairs confer excess risk or risk-mitigating effects could inform
efforts aimed at minimizing harm. Such investigations may require basic science approaches
considering drug effects at the cellular level and using rodent models involving dual drug exposure
and bone-strengthmeasurements. Studies such as ours could inform, justify, and prioritize carefully
designed, narrowly targeted human RCTs that quantify comparative risk of treatment alternatives.
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